1 Title: Low seroprevalence of Ebola virus in health care providers in an endemic region 2 (Tshuapa province) of the Democratic Republic of the Congo 3 Trésor Zola Matuvanga^{1,2,3*}, Joachim Mariën⁴, Ynke Larivière^{2,3}, Bernard Osangir^{2,3}, Solange Milolo¹, Rachel Meta¹, Emmanuel Esanga⁵, Vivi Maketa¹, Junior Matangila¹, Patrick Mitashi¹, 4 5 Steve Ahuka Mundeke⁶, Hypolite Muhindo-Mavoko¹, Jean-Jacques Muyembe Tamfum⁶, Pierre 6 Van Damme², Jean-Pierre Van geertruvden³ 7 **Affiliations** 8 ¹ Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the 9 Congo 10 ² Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of 11 Antwerp, Wilrijk, Belgium 12 ³ Global Health Institute, Department of Family Medicine and Population Health, University of 13 Antwerp, Wilrijk, Belgium. 14 ⁴Department of Biology, Evolutionairy Ecology group, University of Antwerp, Wilrijk, Belgium 15 ⁵Division Provinciale de la Santé de la Tshuapa, Democratic Republic of the Congo 16 ⁶Institut National de Recherches Biomedicales, Department of Virology (INRB) and University of 17 Kinshasa, Service of Microbiology 18 *Corresponding author: Department of Tropical Medicine, University of Kinshasa, Avenue 19 Université numéro 1, Commune de Lemba, Kinshasa, Democratic Repuplic of the Congo, 20 Phone: +243 81004630. 21 Email: zolanga@yahoo.fr 22 23

Page 2 sur 26

2425

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Abstract Introduction: A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods: Serum samples were collected in a cohort of HCPs and frontliners (n=698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results: The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7- 2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA. **Conclusion**: In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas. Key words: EBOV, DRC, EBL2007 trial, GP-EBOV, Luminex, FANG ELISA, Boende, Health care providers, Frontliners.

Abstract words count:195

Page **3** sur **26**

Introduction

48 49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Ebola virus disease (EVD) was first observed during two simultaneous epidemics in 1976 in South Sudan and the Democratic Republic of the Congo (DRC) [1, 2]. Since then, there were fifteen epidemics throughout the DRC, including one in the Boende area, province of Tshuapa in 2014 [3, 4]. The frequency of EVD epidemics in the DRC increased tremendously over the past five years with seven epidemics occurring between 2017 and 2022. Mathematical models predict at least one epidemic each year [5]. The increasing trend can partly be explained by an improved surveillance system and better diagnostic tools. Further, villagers are more likley to come into contact with the natural reservoir of Ebolavirus Zaire (EBOV), as pristine habitats in the Congo Basin are transformed into farmland and cut at an unprecedented rate to provide wood for industries [6]. Human encroachment into these new habitats results in increased bushmeat hunting and a higher level of exposure to the virus, which is most likely spilled over from bats or monkeys [7]. Furthermore, flare-ups of EVD epidemics might also result from chronically infected patients, which was noted recently in Guinea where a survivor passed the virus on to his partner via semen more than 500 days after contracting EVD [5, 8, 9]. While spillover from animals to humans is considered to be rare [10], epidemics are primarily the result of direct person-to-person transmission via body fluids or indirect transmission via contaminated materials [11]. Due to occupational exposure, healthcare providers (HCPs) are more at risk during an outbreak than others in the general community and become a potential source of transmission themselves [12]. For example, during the seventh EVD outbreak in the DRC, which occurred in Boende Health District (2014), three HCPs were identified as potential super-spreaders of community-level disease transmission [13]. Similarly, health facilities may facilitate transmission to the

Page **4** sur **26**

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

community as infected patients, visitors, and the general public come together there [14, 15]. For example, the EBOV epidemic in 1995 was mainly driven by nosocomial transmission at Kikwit General Hospital of DRC [16]. While epidemics are typically monitored through PCR-confirmed active cases. serosurveillance data represents the accumulative number of infections and may detect several undiagnosed cases. Indeed, EBOV infections may remain asymptomatic or paucisymptomatic after exposure to the pathogen [17]. This has been observed in recent studies where EBOV antigen seroreactivity is increasingly reported [8, 18, 19]. In unaffected areas, seroreactivity to EBOV-GP was reported in urban areas of Cameroon (1.3%), and DRC in Kinshasa (2%) and Kasaï Oriental (3.5%) [8, 18, 20, 21]. In a resident pygmy population including traditional hunters in Watsa locality (Haut-Uele province, DRC) a seroprevalence of 18.7% was reported [8]. A study including HCP and frontliners, regardless of their self-reported history of EVD, found 3.4% of EBOV antigens seroreactivity in Kabondo - Dianda (southeastern DRC and forest-savannah area) [22]. A serosurvey conducted at the end of the 2014-2016 epidemic in Sierra Leone showed a seroreactivity of 8% among apparently healthy participants volunteering for an Ebola vaccine trial, with no self-reported history of EVD [23]. Serosurveys in the DRC obtained highly variable seroprevalence estimates depending on the region and the target group. While the EBOV seroprevalence in Boende after the previous epidemic of 2014 was high (28.1%) among healthy HCP never reporting an infection [24], the seroprevalence estimate was much lower in another study conducted in the same area (7%) [22]. A serosurvey conducted on blood samples collected from clinically suspected EVD cases that were sent home after testing negative in two consecutive EBOV RT-PCR during the

Page **5** sur **26**

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

tenth EBOV outbreak in DRC Ituri, Nord Kivu and Sud Kivu provinces, 2018-2020), reported an EBOV antigen seroreactivity of 2.3% [25] (Table 1). However, despite many studies assessing the GP-EBOV antigen seroreactivity in different populations and different locations/countries, the interpretation of this seroprevalence data is challenging given the variation of the assays employed and diversity of cutoff algorithms used [8, 12, 18, 26-28]. Seroreactivity to a single EBOV antigen may not be sufficient to demonstrate prior exposure to EBOV, especially in asymptomatically infected persons [29, 30]. Despite the broad range of EBOV seroprevalence rates in the EBOV endemic areas, previous serological surveys may have overestimated seroprevalence rates due to cross-reactivity against other infectious diseases (i.e. low specificity) [10, 28]. The use of more specific assays to determine the seroreactivity based on at least two antigens may therefore provide a better understanding of the baseline seroprevalence before a vaccine immunogenicity assessment [31, 32]. The study presented here, combines (1) the seroresults of baseline blood samples collected among HCP and frontliners participating in the EBL2007 vaccine trial which evaluates the safety and immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen (ClinicalTrials.gov identifier: NCT04186000) with (2) the results from an ecological survey to determine information related to the current and past residence and work locations of a cohort of HCP included in the EBL2007 vaccine trial [33]. On the baseline blood samples collected, pre-existing antibodies against EBOV among the participants were assessed using both FANG ELISA and Luminex assay. While the first assay only targets IgG antibodies against the glycoprotein (GP) of EBOV, the second assay also tartgets the nucleocapsid (NP) and the viral matrix protein 40 (VP40) which increases its specificity to 99% [34]. This manuscript reports the baseline Page **6** sur **26**

- seroprevalence of Ebolavirus Zaire (EBOV) among HCP and frontliners participants in the
- 121 EBL2007 trial conducted in the health district of Boende in DRC.

Page 7 sur 26

Materials and Methods

Origin of samples

Baseline serum samples were collected before vaccination in an open-label, monocentric, phase 2, randomized trial to evaluate the immunogenicity and safety of Ad26.ZEBOV and MVA-BN-Filo in healthy HCP and frontliners in Boende Health District of DRC (EBL2007 trial, ClinicalTrials.Gov: NCT04186000) [33]. The trial site was located in the Boende General Hospital of Tshuapa province at approximately 750 km north-west of the capital city of Kinshasa in DRC. Blood samples were collected from healthy participants with no reported history of EVD or previous EBOV vaccination. During the first visit of the EBL2007 trial serum samples were collected for baseline determination of IgG GP-EBOV by the means of FANG ELISA and Luminex assay. At one year after inclusion of participants in the EBL2007 vaccine trial, a survey nested within the EBL2007 vaccine trial collected information related to where HCPs and frontliners lived and worked in the past, and their previous contacts with EVD cases.

Operational definition

The HCP term in the EBL2007 vaccine trial included medical doctors, nurses, midwives, laboratory staff, pharmacy staff, hygienists, health facility cleaners, and nursing assistants working in a hospital, Health Center, Health Post, or Health District office. Frontliners encompassed community health workers, first aiders, and those working in the Health District office and or the Provincial Division of Health. Direct contact was defined as any HCP and frontliners who may have had direct interaction with patients infected with EVD at a hospital or treatment center during an outbreak. Indirect contact was considered the

Page **8** sur **26**

work of frontliners and other HCPs whose jobs did not bring them into direct interaction with sick patients but could bring them in contact with contaminated material.

Serological testing

The study was performed according to the good clinical laboratory practice guidelines of the Division of Acquired Immunodeficiency Syndrome and WHO [35, 36] to ensure high quality, reliable, and reproducible data at Q Squared Solutions (San Juan Capistrano, CA, US) Vaccine Testing Laboratory for FANG ELISA and Institut National de Recherche Biomédicale (INRB) in DRC for the Luminex Assay.

LUMINEX Assay technology

The serology testing was performed with Luminex Magpix® technology (Luminex Corp., Austin, TX) as per the previously published protocol [17, 32]. Four recombinant commercially available EBOV antigens were coated onto magnetic beads: two glycoproteins, GP-EBOV-kis (Kissidougou/Makona 2014 strain) and GP-EBOV-m (Mayinga 1976 strain); 1 nucleoprotein, NP-EBOV-m (Mayinga 1976 strain); and 1 40-kDa viral protein (VP40-EBOV-m, Mayinga 1976 strain). The bead-coupled antigens were mixed with the patient sample (1:1000 sample to dilution buffer), and the signal from the response for anti-EBOV immunoglobulin G (anti-IgG) was read and stored on Bio-Plex 200 hardware (Bio-Rad, Marnes-la-Coquette, France). All results were reported as the median fluorescence intensity (MFI). Based on the serological responses, a participant was deemed to bear the pre-existing antibodies against EBOV antigens when the sample was reactive above the cutoff for at least two different EBOV antigens.

Page **9** sur **26**

FANG ELISA

The methods used to perform the FANG ELISA have been described in previous studies [37]. Before the addition of test samples, 96-well microplates were coated with 100 µL of recombinant GP-EBOV-Kikwit (k) and incubated at 4°C in the absence of light. In addition to this, a standard obtained from one or more serially diluted vaccinated donors had been added. Incubation was performed by adding horseradish peroxidase conjugate from goat anti-human IgG to each well. The substrate 3, 3', 5, 5'-tetramethylbenzidine was then incorporated into each well. The addition of sulfuric acid solution stopped the enzymatic reaction. The color change was then observed with a plate reader. The plate reader was used to report the quality controls as well as the concentrations of the added samples. The concentrations of these samples were based on the standard curve calculated using a 4-parameter logistic curve (4PL) and are expressed as ELISA units/ml (EU/ml). Final titers were determined based on a cutoff optical density (OD) value and were reported as the reciprocal of the highest dilution with a positive OD value.

Sample Size and Statistical Analysis

The number of participants eligible for the EBL2007 trial with available aliquots (n=698) at the inclusion visit predetermined the number of enrolled subjects in the serosurvey. Subjects reacting to EBOV antigens (GP, NP, VP40) were summarized using proportions with 95% confidence interval. Demographic and ecological data were compiled and summarized using descriptive statistics for all participants enrolled in the EBL2007 vaccine trial using SPSS 28.0 IBM SPSS Statistics for Windows, version 28.0 and R 4.2.1 Statistical Software.

Page 10 sur 26

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

Both the FANG ELISA and Luminex assay do not have an established cutoff to distinguish individuals with seroreactivity to an EBOV antigen. In the absence of a representive control panel to estimate a cutoff, we calculated cutoff values by change point analysis [38] using R [39]. In the supplementary information, we also provide seroprevalence estimates based on cutoff values obtained from literature. To further investigate if the signal of the antibody assay represents true past exposure to EBOV, we tested if participants from the EBOV risk groups (based on age, sex, direct or indirect contact with patients in general, working in a hospital or elsewhere, previous contact with Ebola patients or experienced an outbreak at a location where you lived) were significantly more likely to be antibody positive. We used a generalized linear model with binomial link function. For each individual antigen, the participant's seropositivity status was included as response variable and the participant characteristics as explanatory variables. Only combinations of the Luminex GP-EBOV-m+VP40-EBOV were considered, as the sample size of the positive group was too small for all other combinations. P-values were considered significant below a value of 0.05.

Page 11 sur 26

Ethics statements

The National Ethics Committee of the DRC Ministry of Health approved the study protocol of EBL2007 (approval reference n°121/CNES/BN/PMMF/2019). The ecological survey nested in the EBL2007 Vaccine trial was approved by the National Ethics Committee of the DRC Ministry Health under approval reference n°212/CNES/BN/PMMF/2020. For both the EBL2007 trial and the ecological survey participants provided written informed consent.

Results

Participants characteristics

A total of 720 HCPs and frontliners were screened for inclusion in the EBL2007 trial, of which 699 (96.9%) agreed to participate in the baseline seroprevalence study. However, one participant withdrew consent prior to blood collection. Thus, blood samples were available for 698 (99.9%) participants with a mean age of 45 years (standard deviation=12.0) and 534 (76.5%) were male (**Table 2**). Nearly two-thirds of the HCPs and frontliners [492 (70.5%)] worked in a health facility in the Boende Health District and 410 (59.0%) were HCPs working in direct contact with patients. Forty-three (6.2%) of them reported a direct contact with patients during a previous Ebola outbreak in Boende or elsewhere. From a minority (3.5%) we are not sure if they ever had contact with infectious patients during an ebola outbreak.

Page 12 sur 26

231232

233234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

Seroreativity to EBOV proteins using FANG ELISA and or Luminex When considering antibody responses against EBOV antigens individually, we found that 8.4% (59/698; 95%CI 6.5 -10.6) of samples tested positive on the Luminex for GP-EBOVm, 9.4% (66/698;95%CI 7.5 -11.8) for GP- EBOV-kis, 9.4% (87/698;95%CI10.3-12.9) for VP40-EBOV-m, and 1.3% (9/698;95%Cl0.6-2.6) for NP-EBOV-m (Table 3). The seroreactivity to at least two EBOV antigens using Luminex was encountered in 1.4% (10/698;95%CI0.7-2.6) and 0.3% (2/698;95%CI0.0-1.0) of sera for VP40-EBOV-m + GP-EBOV-m and VP40-EBOV-m + NP-EBOV-m respectively. No sera tested positive for NP-EBOV-m+GP-EBOV-m. GP-EBOV-m seroreactivity on the FANG ELISA was found in 7.1% (49/698; 95%Cl6.5-10.9) of participants' sera. Looking at participants whose GP-EBOV seroreactivity was identified in both Luminex and FANG ELISA, 0.8% (6/694; 95%Cl0.1-1.5) of the tested samples were positive. We performed seroreactivity analyses using cutoffs determined in the literature and found similar results as depicted in the Supplementary material. A weak correlation between the FANG ELISA and Luminex was shown (k=0.2) (Figure 1). In seeking which participant characteristics influenced seropositivity, we observed significant differences in the seropositivity rate between HCPs and frontliners who previously made direct contact with an Ebola patient or experienced an outbreak in their hometown. When looking at the GP-EBOV-k antigen, HCPs and frontliners who previously became into contact with Ebola were significantly less likely to be seropositive compared to HCPs and frontliners who never experienced an Ebola outbreak (estimate=-1.22, std. error = 0.52, P=0.02). When looking at the GP-EBOV-m, seropositivity status significantly decreased with age (estimate = -0.02, est.error = 0.01, P=0.04).

Page 13 sur 26

Discussion

256257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

We report the baseline seroreactivity to EBOV-m antigens in apparently healthy HCPs and frontliners enrolled in the EBL2007 vaccine trial. Based on seroreactivity in two different assay formats (FANG ELISA and Luminex), only a minority (0.8%) of HCPs and frontliners blood samples seroreacted to the GP-EBOV-m surface antigen. Similarly, a minority of participants sera tested positive to at least two antigens on the Luminex (0.3% for NP+VP40 EBOV-m and 1.4 for GP-EBOV-m+VP40-EBOV-m). None of the participants sera tested positive to GP-EBOV-m+NP-EBOV-m. Additionally, when we investigated whether seropositivity correlated with participants' prior exposure to EBOV-m, we did not observe a relevant positive correlation. This suggests that the majority of seropositive participants implied on the basis of the single antigen analysis are in fact false positives. Overall, these results suggest that the baseline seroprevalence against EBOV-m in HCPs and frontliners in Boende is very low. Our seroprevalence estimates are much lower compared to previous serosurveys conducted after the EVD outbreak of 2014 in HCP of Boende Health District (22.5% and 28%) (GP-EBOV-m seroreactivity using ELISA) [12, 27]. Our estimates are also lower than the one previously reported in Boende Health District among the general population (7%) (GP-EBOV-m seroreactivity using ELISA) a year after the 2014 Ebola epidemic [22]. The seroprevalence based on one EBOV-m antigen (GP-EBOV-m) found in this study using either ELISA or Luminex is lower than other peviously reported in the Watsa Pygmy population of DRC in 2002 (18.7%) (GP-EBOV-m seroreactivity using ELISA) and the Sankuru rural population in 2007 (11%) (GP-EBOV-m seroreactivity using ELISA) [8, 21].

Page **14** sur **26**

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

By employing this approach, our seroprevalence estimates became comparable to those of previous serological surveys conducted in Kikwit (2.2%) (GP-EBOV-m seroreactivity by ELISA) and Kinshasa (2%) (GP-EBOV-m seroreactivity by luciferase immunoprecipitation system + neutralization) [18, 40]. It is worth noting that LUMINEX built on an approach of simultaneously targeting multiple EBOV antigens, demonstrated a specificity (99.1%) and a sensitivity (95.7%) similar to higher than, respectively, the specificity (100%) and sensitivity (92.5%) of the commercial ELISA in a study [32]. The FANG ELISA was developed and validated to quantify Filovirus anti-EBOV-GP immunoglobulin G (IgG) binding antibodies in human and non-human primate serum sample to enable bridging of immunogenicity data between humans and animal models in vaccine trials [37]. The higher seroprevalences found in other serosurveys conducted in Boende or elsewhere in the DRC may be explained by the fact that different assays were used in the different studies, other cutoff algorithms were used, and the definition of reactivity discrimination (one or two EBOV antigens) may have decreased the specificity of these assays. This could have led to overestimation of EBOV antigen seropositivity. On the other hand, it cannot be ruled out that more people were indeed infected during the 2014 outbreak in Boende and that antibody titers waned over time or at least dropped below the detection threshold, explaining the low seroprevalence that we observed. Likewise, this low prevalence may reflect a rare incidence of asymptomatic EBOV infection among HCP and frontliner population from the Boende Health District. The previous scenario may reflect a susceptibility to future outbreaks of EBOV. Yet, negative antibody titers doe not rule out other types of immunity, such asT-cell immunity [41].

Page 15 sur 26

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

FANG ELISA or Luminex are assays that can only detect binding antibodies and are unable to differentiate them from neutralizing antibodies [37]. The latter are typically detected using neutralization assays, which are still considered the gold standard for serological testing [42, 43]. However, such testing involves infectious cells, are labour intenstive and time consuming [44]. For viruses such as EBOV, all experiments should be performed under a biosafety laboratory (BSL)-4 conditions, which are limited in availability and expensive to operate [45]. Thus, it is beneficial to use alternative neutralization assays that do not require viruses or live cells, and that can be performed in BSL-2 laboratories to assess neutralizing antibody capacity [44, 46]. These alternative assays should conclude if a person with high binding antibodies against EBOV (based on FANG ELISA or Luminex) was indeed infected with the virus (although some level of cross-reactivity can never be ruled out) [29]. The challenge of comparing different serosurveys that have assessed the EBOV seroprevalence makes the implementation of international standardization of units for EBOV antibody detection and quantification of paramount importance [47]. The poor linear relationship between the two assays used (FANG ELISA and Luminex) in this serosurvey confirms that both assays likely contain many false positive results, when using single antigens. Hence, the reported seropositivity could be an effect of other filoviruses or infectious microbes, which may cause cross-reactions [48]. A limitation of our study is the lack of positive and negative control samples to determine the positive cutoff. However, in the absence of a standard serological assay for EBOV seroreactivity, Luminex can still be employed in serosurveys due to its ability to detect seroreactivity to combinations of different EBOV antigens [32].

Page 16 sur 26

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

The strength of this survey resides in the use of high cutoffs to determine the EBOV seropositivity that aligns with recommendations in EBOV serosurveys generally applied to Congolese cohorts [18, 28, 49]. Thus, the combination of FANG ELISA and Luminex results can be considered a starting point, showing how previous serological surveys may have overestimated the seroprevalence of EBOV in a non-exempt area. Like the recent index case of the fourteenth outbreak in DRC (Mbandaka, 2022), whose symptoms began three weeks after returning from Boende with no notion of contact with an Ebola survivor [5]. The next step could be the use of a neutralization assay for assessment of neutralizing antibodies among this population of HCP and frontliners participants in the EBL2007 trial to further document whether or not this population of HCP is naive to EBOV exposure. The low baseline seroreactivity to EBOV antigens observed in HCP and frontliner population of Boende suggests that the majority of this population never came into contact with the virus, despite the fact the many HCP and frontliners worked during previous EBV outbreak in 2014. In the event of a future epidemic, mathematical models suggested that the vaccination rate of HCP in an infected area should be at least (30%) to prevent a major epidemic [50]. Therefore it is clear that HCP in endemic regions should be primary targets for vaccination in the frame of the Ebola epidemic preparedness plan in DRC [50].

Page 17 sur 26

Conclusion

In contrast to previous studies that observed high seroreactivity against EBOV-m in Boende, our results show that the baseline seroprevalence of HCP and frontliners that reported no previous EBOV infections is low. This suggests that asymptomatic infections are unlikely to occur or that antibodies rapidly wane after infection (or at least drop below the cutoff of detection). Irrespective of the cause, it means that the majority of HCPs in the area are likely susceptible to EVD despite the history of outbreaks in and the area of Boende. Given the high variance between seroprevalence estimates by different studies in the same region, we highlight the need for more uniform antibody assays. Neutralizing antibody quantification methods, which are inexpensive in terms of resources, are likely to be crucial for improving EVD surveillance in this region, given the high background of concomitant parasitic disease burden that can be expected to be found in the serum of this population. Low resources affordable approaches to quantifying neutralizing antibodies are likely to be crucial in enhancing surveillance of EVD disease in this region.

Acknowledgments

The authors gratefully acknowledge the hard work and dedication of the local trial staff.

The supportive role of ACE Research, DFNet Research, Q² Solutions and Institut National

de Rechrche Biomédicale (INRB) and all partners within the EBOVAC3 Consortium is

highly appreciated.

Page 18 sur 26

Financial support

This work was supported by the EBOVAC3. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 800176 (IMI-EU). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation pro-gramme, European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Coalition for Epidemic Preparedness Innovations (CEPI). All vaccines were provided by Janssen Vaccines & Prevention B.V.

Potential conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Page 19 sur 26

References

377

378

- Team WIS: **Ebola haemorrhagic fever in Sudan, 1976**. *Bulletin of the World Health Organization* 1978, **56**(2):247-270.
- 381 2. **Ebola haemorrhagic fever in Zaire, 1976**. *Bull World Health Organ* 1978, **56**(2):271-293.
- 382 3. Epidémie de la Maladie à Virus Ebola, Province de l'Equateur, République Démocratique du Congo (24/04/2022) [https://reliefweb.int/organization/who]
- 384 4. Le Gouvernement déclare la fin de l'épidémie de la maladie à virus Ebola dans la Zone de santé de Boende | Province de l'Equateur, Nord-ouest de la RDC [https://reliefweb.int/organization/who]
- 387 5. Makoni M: **Ebola outbreak in DR Congo**. *The Lancet* 2022, **399**(10337):1766.
- Tyukavina A, Hansen MC, Potapov P, Parker D, Okpa C, Stehman SV, Kommareddy I, Turubanova S: **Congo Basin forest loss dominated by increasing smallholder clearing**. *Science advances* 2018, **4**(11):eaat2993.
- Gryseels S, Mbala-Kingebeni P, Akonda I, Angoyo R, Ayouba A, Baelo P, Mukadi DB, Bugentho E,
 Bushmaker T, Butel C et al: Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati),
 Democratic Republic of the Congo, 2017. Emerg Infect Dis 2020, 26(9):2205-2209.
- 394 8. Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A, Swanepoel R, Muyembe-395 Tamfum J-J, Van der Stuyft P: **High prevalence of IgG antibodies to Ebola virus in the Efé pygmy** 396 **population in the Watsa region, Democratic Republic of the Congo**. *BMC infectious diseases* 397 2016, **16**(1):1-6.
- Diallo B, Sissoko D, Loman NJ, Bah HA, Bah H, Worrell MC, Conde LS, Sacko R, Mesfin S, Loua A:
 Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in
 seminal fluid for more than 500 days. Clinical infectious diseases 2016, 63(10):1353-1356.
- 401 10. de La Vega M-A, Stein D, Kobinger GP: **Ebolavirus evolution: past and present**. *PLoS pathogens* 402 2015, **11**(11):e1005221.
- 403 11. Dhama K, Malik YS, Malik SVS, Singh RK: **Ebola from emergence to epidemic: the virus and the**404 **disease, global preparedness and perspectives**. *The Journal of Infection in Developing Countries*405 2015, **9**(05):441-455.
- 406
 Doshi RH, Hoff NA, Bratcher A, Mukadi P, Gadoth A, Nicholson BP, Williams R, Mukadi D,
 Mossoko M, Wasiswa J: Risk Factors for Ebola Exposure in Health Care Workers in Boende,
 Tshuapa Province, Democratic Republic of the Congo. The Journal of Infectious Diseases 2020.
- 409 13. Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, Mondonge V, Muyembe J-JT, Bertherat E, Briand S: **Ebola virus disease in the Democratic Republic of** 411 **Congo**. *New England Journal of Medicine* 2014, **371**(22):2083-2091.
- 412 14. **History of Ebola Virus Disease (EVD) Outbreaks**413 [https://www.cdc.gov/vhf/ebola/history/chronology.html]
- 414 15. Baller A, Padoveze MC, Mirindi P, Hazim CE, Lotemo J, Pfaffmann J, Ndiaye A, Carter S, Chabrat
 415 M-AD, Mangala S: **Ebola virus disease nosocomial infections in the Democratic Republic of the**416 **Congo: a descriptive study of cases during the 2018–2020 outbreak**. *International Journal of*417 *Infectious Diseases* 2022, **115**:126-133.
- 418 16. Muyembe-Tamfum J, Kipasa M, Kiyungu C, Colebunders R: **Ebola outbreak in Kikwit, Democratic**419 **Republic of the Congo: discovery and control measures**. *The Journal of infectious diseases* 1999,
 420 **179**(Supplement_1):S259-S262.
- Diallo MSK, Rabilloud M, Ayouba A, Touré A, Thaurignac G, Keita AK, Butel C, Kpamou C, Barry
 TA, Sall MD: Prevalence of infection among asymptomatic and paucisymptomatic contact

Page 20 sur 26

- persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.

 The Lancet Infectious Diseases 2019, **19**(3):308-316.
- 425 18. Steffen I, Lu K, Yamamoto LK, Hoff NA, Mulembakani P, Wemakoy EO, Muyembe-Tamfum JJ, 426 Ndembi N, Brennan CA, Hackett J, Jr. *et al*: **Serologic Prevalence of Ebola Virus in Equatorial** 427 **Africa**. *Emerg Infect Dis* 2019, **25**(5):911-918.
- 428 19. Shaffer KC, Hui S, Bratcher A, King LB, Mutombe R, Kavira N, Kompany JP, Tambu M, Musene K,
 429 Mukadi P: Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health
 430 Region, Democratic Republic of the Congo. PLOS Neglected Tropical Diseases 2022,
 431 16(3):e0010167.
- 432 20. Moyen N, Thirion L, Emmerich P, Dzia-Lepfoundzou A, Richet H, Boehmann Y, Dimi Y, Gallian P, Gould EA, Günther S: **Risk factors associated with Ebola and Marburg viruses seroprevalence in blood donors in the Republic of Congo**. *PLoS neglected tropical diseases* 2015, **9**(6):e0003833.
- 435 21. Mulangu S, Alfonso VH, Hoff NA, Doshi RH, Mulembakani P, Kisalu NK, Okitolonda-Wemakoy E, Kebela BI, Marcus H, Shiloach J: **Serologic evidence of ebolavirus infection in a population with no history of outbreaks in the Democratic Republic of the Congo**. *The Journal of Infectious Diseases* 2018, **217**(4):529-537.
- 439 22. Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
 440 Spencer D, Bramble MS *et al*: **Zoonotic risk factors associated with seroprevalence of Ebola**441 **virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic**442 **of Congo.** *PLoS Negl Trop Dis* 2021, **15**(8):e0009566.
- 443 23. Manno D, Ayieko P, Ishola D, Afolabi MO, Rogers B, Baiden F, Serry-Bangura A, Bah OM, Köhn B, Swaray I *et al*: **Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected**445 **by Ebola, Sierra Leone**. *Emerg Infect Dis* 2022, **28**(3):734-738.
- Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer D, Nicholson BP,
 Williams R et al: Serologic Markers for Ebolavirus Among Healthcare Workers in the
 Democratic Republic of the Congo. J Infect Dis 2019, 219(4):517-525.
- Nkuba-Ndaye A, Mukadi-Bamuleka D, Bulabula-Penge J, Thaurignac G, Edidi-Atani F, Mambu Mbika F, Danga-Yema B, Matondo-Kuamfumu M, Kinganda-Lusamaki E, Bisento N: Added value
 of an anti-Ebola serology for the management of clinically suspected Ebola virus disease
 patients discharged as negative in an epidemic context. The Journal of Infectious Diseases 2022.
- 453 26. Mbala P, Baguelin M, Ngay I, Rosello A, Mulembakani P, Demiris N, Edmunds WJ, Muyembe J-J: 454 **Evaluating the frequency of asymptomatic Ebola virus infection**. *Philosophical Transactions of the Royal Society B: Biological Sciences* 2017, **372**(1721):20160303.
- 456 27. Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer DA, Nicholson BP,
 457 Williams R: Serologic markers for ebolavirus among healthcare workers in the Democratic
 458 Republic of the Congo. The Journal of infectious diseases 2019, 219(4):517-525.
- 459 28. Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
 460 Spencer DA, Bramble MS: **Zoonotic risk factors associated with seroprevalence of Ebola virus**461 **GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of**462 **Congo.** *PLoS Neglected Tropical Diseases* 2021, **15**(8):e0009566.
- 463 29. Richardson ET, Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, Marsh RH, Koedoyoma S,
 464 Daboh F, Barron KP: **Minimally symptomatic infection in an Ebola 'hotspot': a cross-sectional**465 **serosurvey**. *PLoS neglected tropical diseases* 2016, **10**(11):e0005087.
- 466 30. Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM: **Identification of continuous human B-cell**467 **epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus**. *PloS one* 2014,
 468 **9**(6):e96360.
- 469 31. Rudge Jr TL, Sankovich KA, Niemuth NA, Anderson MS, Badorrek CS, Skomrock ND, Cirimotich CM, Sabourin CL: **Development, qualification, and validation of the Filovirus Animal Nonclinical**

Page 21 sur 26

- 471 Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay 472 for human serum samples. *PloS one* 2019, **14**(4):e0215457.
- 473 32. Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
 474 Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for
 475 Detection of Antibodies to Zaire Ebola Virus. *J Clin Microbiol* 2017, **55**(1):165-176.
- Larivière Y, Zola T, Stoppie E, Maketa V, Matangila J, Mitashi P, De Bie J, Muhindo-Mavoko H, Van Damme P: **Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of**a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. *BMJ open*2021, **11**(9):e046835.
- 481 34. Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
 482 **Development of a sensitive and specific serological assay based on Luminex technology for**483 **detection of antibodies to Zaire Ebola virus**. *Journal of clinical microbiology* 2017, **55**(1):165484 176.
- 485 35. Health NIo: **Guidelines for good clinical laboratory practice standards**. *Bethesda, MD, USA:* 486 *National Institutes of Health* 2019.
- 487 36. Stevens W: Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory practice and good clinical practice guidelines/standards for medical testing laboratories conducting clinical trials in developing countries. Quality Assurance 2003, 10(2):83-89.
- 490 37. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Pettitt J, Stavale EJ, Fallah M,
 491 Olinger GG: **Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay**492 **requires fewer study participants to power a study than the Alpha Diagnostic International**493 **assay.** *Journal of virological methods* 2018, **255**:84-90.
- 494 38. Lardeux F, Torrico G, Aliaga C: **Calculation of the ELISA's cut-off based on the change-point**495 **analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence**496 **of controls**. *Mem Inst Oswaldo Cruz* 2016, **111**(8):501-504.
- 497 39. Killick R, Eckley I: **changepoint: An R package for changepoint analysis**. *Journal of statistical* 498 *software* 2014, **58**(3):1-19.
- 499 40. Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, Feldmann H, Khan AS, Peters C:
 500 Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic
 501 Republic of the Congo, 1995. The Journal of Infectious Diseases 1999, 179 (Supplement_1):S102502 S107.
- 503 41. Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK, Krähling V, Steeds K *et al*: **Longitudinal antibody and T cell responses in Ebola virus disease** survivors and contacts: an observational cohort study. *Lancet Infect Dis* 2021, **21**(4):507-516.
- 42. Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA, Mukadi P, Nicholson BP, Alfonso VH,
 507 Olinger G: Ebola virus neutralizing antibodies detectable in survivors of theYambuku, Zaire
 508 outbreak 40 years after infection. The Journal of infectious diseases 2018, 217(2):223-231.
- 509 43. Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, Kaushal H, Deshpande KS, Kaduskar O, Sarkale P: **Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients**.
 511 The Indian journal of medical research 2020, **152**(1-2):82.
- Mariën J, Michiels J, Heyndrickx L, Nkuba-Ndaye A, Ceulemans A, Bartholomeeusen K, Madinga J,
 Mbala-Kingebeni P, Vanlerberghe V, Ahuka-Mundeke S: Evaluation of a surrogate virus
 neutralization test for high-throughput serosurveillance of SARS-CoV-2. Journal of Virological
 Methods 2021, 297:114228.
- Burnett LC, Lunn G, Coico R: **Biosafety: guidelines for working with pathogenic and infectious** microorganisms. *Current protocols in microbiology* 2009, **13**(1):1A. 1.1-1A. 1.14.

Page 22 sur 26

| 518 | 46. | Cao Z, Jin H, Wong G, Zhang Y, Jiao C, Feng N, Wu F, Xu S, Chi H, Zhao Y: The Application of a |
|-----|-----|--|
| 519 | | Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus. Virologica |
| 520 | | Sinica 2021, 36 (6):1648-1651. |

- 521 47. WHO International Standard 1st International Standard for Ebola virus (EBOV) antibodies 522 Sierra Leone Convalescent Plasma Pool NIBSC code: 15/262 Instructions for use
 523 [https://www.nibsc.org/documents/ifu/15-262.pdf]
- 524 48. MacNeil A, Reed Z, Rollin PE: **Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus**. *PLoS neglected tropical diseases* 2011, **5**(6):e1175.
- 526 49. Kuhn J: Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory studies. 2008.
- 528 50. Potluri R, Kumar A, Maheshwari V, Smith C, Oriol Mathieu V, Luhn K, Callendret B, Bhandari H: 529 Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis. 530 Plos one 2020, **15**(4):e0230406.

Page 23 sur 26

Table 1. EBOV seroprevalence estimates using different Assays in DRC

| Area of DRC | Year | *EBOV Seroprevalence (%) | Assay | CI | Population | Sample size (N) | Studies |
|---|----------------|--------------------------------|--|-------------|--|--------------------|---|
| Kikwit | 1995 | 2.2 | ELISA | 0.3 – 4.0 | Forest and City Workers | 414 | Busico et al. Journal of Infectious Diseases 1999, 79: S102-S107. |
| Watsa | 2002 | 18.7 | ELISA | 14.4 – 23.5 | General popualtion (pygmy) | 300 | Mulangu et al. <i>BMC</i> infectious diseases 2016, 16.1: 1-6 |
| Sankuru | 2007 | 11.0 | ELISA | 9.9 –12.7 | General population | 3415 | Mulangu et al. The Journal of Infectious Diseases 2018, 217.4: 529-537 |
| Kinshasa | 2011 – 2012 | 2.0 | Luciferase immunoprecipitation system + neutralization | 0.7 – 5.1 | Blood donors | 752 | Imke et al., Emerging Infectious Diseases. 25 (5) 2019 |
| Boende | 2015 | 22.5 | ELISA | 19.2 – 25.9 | Healthcare workers | 611 | Doshi et al. The Journal of Infectious Diseases (2020). |
| Boende | 2015 | 28.1 | ELISA, Luciferase immunoprecipitation system + neutralization | 24.4 – 31.4 | Healthcare workers | 565 | Hoff et al. The Journal of infectious diseases, 2019, 219.4: 517-525 |
| Boende | 2015 – 2017 | 7.0 | ELISA | 5.0 – 8.8 | General population | 687 | Bratcher et al. <i>PLoS</i> Neglected Tropical Diseases, 2021, 15.8: e0009566. |
| Beni, Butembo, Katwa, and Mabalako | 2018- 2020 | 2.3 | Luminex assay | 1.1–4.0 | Suspected cases of the tenth DRC epidemic of Ebola | 600 | Nkuba-Ndaye et al. <i>J Infect Dis</i> . 2022 ;226(2):352-356 |

*Seroprevalence based on the GP-EBOV antigen seroreactivity

Page **24** sur **26**

533

Table 2. Participants characteristics

| Age (year) 45.0 (12.0) 19 75 Sex Female 164 23.5 Male 534 76.5 Profession 76.5 Community Health Worker 236 33.8 Nurse 181 25.9 First Aid Worker 177 25.4 Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 1 0.4 Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician 2 0.3 Pharmacist 2 0.3 Assistant 492 70.5 Santé) 492 70.5 Health Facility 492 70.5 Health Facility 6 492 70.5 Santé) 6 20 40 | Characteristic | N=698 | % Max | Mean (SD) | Min | |
|--|--|-------|----------|-------------|-----|----|
| Male 534 76.5 Profession 236 33.8 Community Health Worker 236 33.8 Nurse 181 25.9 First Aid Worker 177 25.4 Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician 2 0.3 Pharmacist 2 0.3 Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé, Poste de Santé, Poste de Santé 5 Santé, Poste de Santé 1.1 2 Santé 0 1.5 Health District Office (Bureau central 8 1.1 Zone de Santé 0 0.1 Santé 1 0.1 | | | | 45.0 (12.0) | 19 | 75 |
| Profession | Female | 164 | 23.5 | | | |
| Community Health Worker 236 33.8 Nurse 181 25.9 First Aid Worker 177 25.4 Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 7 1.0 Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician Pharmacist 2 Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé, Poste de Santé, Poste de Santé) 5 Gureau central 8 1.1 Zone de Santé) 2 70.5 Croix-Rouge 8 1.1 Boende 177 25.4 Inspection 1 0.1 Provinciale de la 1 0.1 Aire de Santé 10 1.4 | Male | 534 | 76.5 | | | |
| Nurse | Profession | | | | | |
| Nurse 181 25.9 First Aid Worker 177 25.4 Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility Cleaner Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician Pharmacist 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Community Health | 226 | 22.0 | | | |
| First Aid Worker 177 25.4 Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility Cleaner 10 1.4 Cleaner 2 0.3 Laboratory 2 0.3 Technician Pharmacist Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Worker | 230 | 33.0 | | | |
| Hygienist 37 5.3 Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician Pharmacist 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Nurse | 181 | 25.9 | | | |
| Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 7 1.0 Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician 2 0.3 Pharmacist 2 0.3 Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé, Poste de Santé, Poste de Santé 492 70.5 Santé) 492 70.5 5 Bureau central 8 1.1 Zone de Santé) 177 25.4 Boende Inspection 1 Provinciale de la 1 0.1 Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | First Aid Worker | 177 | 25.4 | | | |
| Midwife 30 4.3 Medical Doctor 13 1.9 Health Facility 10 1.4 Cleaner 7 1.0 Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician 2 0.3 Pharmacist 2 0.3 Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé, Poste de Santé, Poste de Santé 492 70.5 Santé) 492 70.5 5 Bureau central 8 1.1 Zone de Santé) 177 25.4 Boende Inspection 1 Provinciale de la 1 0.1 Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Hygienist | 37 | 5.3 | | | |
| Health Facility Cleaner Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Technician Pharmacist 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé el a Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | 30 | 4.3 | | | |
| Cleaner Care Giver 7 1.0 Other 3 0.4 Laboratory 2 0.3 Pharmacist 2 0.3 Assistant 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé el Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Medical Doctor | 13 | 1.9 | | | |
| Care Giver 7 1.0 Other 3 0.4 Laboratory Technician Pharmacist 2 0.3 Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | - | 10 | 1.4 | | | |
| Other | | 7 | 1.0 | | | |
| Laboratory Technician Pharmacist Assistant Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 1777 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | | | | | |
| Technician Pharmacist Assistant Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 1777 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Laboratory | | | | | |
| Pharmacist Assistant Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | 2 | 0.3 | | | |
| Assistant Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | _ | | | | |
| Place of work in Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | 2 | 0.3 | | | |
| Boende Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | | | | | |
| Health Facility (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | | | | | |
| (Hopital, Centre de Santé, Poste de Santé) Health District Office (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | | | | | |
| (Bureau central 8 1.1 Zone de Santé) Croix-Rouge 177 25.4 Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | (Hopital, Centre de Santé, Poste de | 492 | 70.5 | | | |
| Zone de Santé) Croix-Rouge Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Health District Office | | | | | |
| Croix-Rouge Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | • | 8 | 1.1 | | | |
| Boende Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | | | | | |
| Inspection Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | | 177 | 25 4 | | | |
| Provinciale de la 1 0.1 Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Boende | 177 | 20.4 | | | |
| Santé Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Inspection | | | | | |
| Aire de Santé 10 1.4 Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Provinciale de la | 1 | 0.1 | | | |
| Division Provinciale de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Santé | | | | | |
| de la Santé 9 1.3 Tshuapa Programme Elargi de Vaccination 1 0.1 | Aire de Santé | 10 | 1.4 | | | |
| Tshuapa Programme Elargi de Vaccination 1 0.1 | Division Provinciale | | | | | |
| Programme Elargi de Vaccination 1 0.1 | de la Santé | 9 | 1.3 | | | |
| Programme Elargi de Vaccination 1 0.1 | | | | | | |
| de Vaccination 1 0.1 | | | | | | |
| | | 1 | 0.1 | | | |
| | | | | | | |

535

536

Table 3: Seroprevalence for different (combinations of) antibodies against Ebola virus antigens as measured by the Luminex or FANG ELISA in Health care providers from Boende, DRCongo.

| | Antigen | *Cutoff | Positives | Seroprevalence | Age /year | M vs F | Direct Contact with patients: Direct vs indirect | Working Hospital vs elsewhere | Experienced Ebola outbreak/patients vs others |
|---------------------------------|-------------------------------|-------------------------|-----------|--------------------|-----------|---------|--|----------------------------------|---|
| | | | n (N) | % (95% conf. Int.) | p-value | p-value | (p-value) | (p-value) | p-value |
| FANG ELISA | GP-EBOV-k | 526 EU/ml | 59 (694) | 8.5 (6.5, 10.9) | 0.89 | 0.44 | 0.52 | 0.93 | 0.94 |
| | GP-EBOV-m | 669 MFI/100 beads | 60 (698) | 8.6 (6.5,10.7) | 0.03 | 0.93 | 0.05 | 0.63 | 0.09 |
| | GP-EBOV-kis | 670 MFI/100 beads | 66 (698) | 9.4 (7.5,11.8) | 0.05 | 0.99 | 0.05 | 0.52 | 0.005 |
| | VP40-EBOV- m | 441 MFI/100 beads | 87 (698) | 12.4 (10.3,14.9) | 0.11 | 0.07 | 0.31 | 0.74 | 0.46 |
| Luminex | NP-EBOV-m | 602 MFI/100 beads | 9 (698) | 1.3 (0.6,2.6) | 0.41 | 0.40 | 0.13 | 0.26 | 0.07 |
| | GP-EBOV- m+NP- EBOV-m | C1 | 0 (698) | 0 | | | | | |
| | GP-EBOV- m+VP40- EBOV-m | C2 | 10 (698) | 1.4 (0.7,2.6) | 0.75 | 0.02 | 0.39 | 0.68 | 0.47 |
| | NP-EBOV- m+VP40- EBOV-m | С3 | 2 (698) | 0.3 (0.0,1.0) | | | | | |
| Luminex and FANG ELISA | GP-EBOV-m + GP-EBOV-k | C4 | 6 (694) | 0.8 (0.1,1.5) | | | | | |

C1= 669MFI/100 beads for GP-EBOV-m and 602 MFI/100 beads for NP-EBOV-m

C2= 669MFI/100 beads for GP-EBOV-m and 441 MFI/100beads fo VP40-EBOV-m

C3= 602 MFI/100 beads for NP-EBOV-m and 441 MFI/100 beads for VP40-EBOV-m

C4= 669 MFI/100 beads for GP-EBOV-m using Luminex and 526 EU/mL for GP-EBOV-k using FANG ELISA

Page 26 sur 26




Figure 1 Pearson Correlation between FANG ELISA and Luminex Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from Boende. The X axis reports the log values of the antibody titers (IgG) as measured by Luminex in MFI/100 beads, while the Y axis represents antibody titers as measured by FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the changepoint analysis and the dashed horizontal line in green represents the cutoff obtained from previous studies.




Figure 1 Pearson Correlation between FANG ELISA and Luminex

Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from Boende. The X-axis reports the log values of the antibody titers (IgG) as measured by Luminex in MFI/100 beads, while the Y-axis represents antibody titers as measured by FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the changepoint analysis and the dashed horizontal line in green represents the cutoff obtained from previous studies.